It is expected that the next phase will be completed during the first half of 2008 and that larger-scale independently-managed formal Clinical Trials, leading to a licensed product in Europe, will take place shortly thereafter at a world-renowned specialist wound healing clinic.
"The success of this phase of the trial is yet another substantial milestone in moving toward approval of SF-1019 in Europe for use with Diabetic Ulcers," said Stephen D. Ferrone, President and CEO of Immunosyn. "We feel that beyond whatever the potential revenue might be for Immunosyn, from possible future approval and sales of SF-1019, is the significant and compassionate role that SF-1019 could eventually play in filling an unmet need in the arena of wound healing. According to the International Diabetes Federation (IDF), of the 250 million people globally who suffer from Diabetes Mellitus one out of six will develop a Diabetic Ulcer. To put that into perspective, currently, worldwide, one person every 30 seconds has a limb amputated due to Diabetes, 85% of which are preceded by a Diabetic Ulcer; and, as unbelievable as it seems, until now there have been no known therapies to remedy this tragic condition," concluded Mr. Ferrone.
About Immunosyn Corporation
La Jolla, CA-headquartered Immunosyn Corporation (IMYN.OTC.BB) plans to
market and distribute life enhancing therapeutics. Currently, the company
has exclusive worldwide rights from its largest shareholder, Argyll
Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound
that was developed from extensive research into Biological Response
Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for
regulatory approval of SF-1019 in several countries and preparations for
clinical trials are underway in both the US and Europ
|SOURCE Immunosyn Corporation|
Copyright©2008 PR Newswire.
All rights reserved